Evolution of ramucirumab in the treatment of cancer – A review of literature

@article{Vennepureddy2017EvolutionOR,
  title={Evolution of ramucirumab in the treatment of cancer – A review of literature},
  author={A. Vennepureddy and P. Singh and R. Rastogi and J. Atallah and T. Terjanian},
  journal={Journal of Oncology Pharmacy Practice},
  year={2017},
  volume={23},
  pages={525 - 539}
}
Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies. Its mechanism of action is by inhibiting angiogenesis in tumor cells by targeting the vascular endothelial growth factor receptor 2. United States Food and Drug Administration (FDA) approved it initially in 2014 for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma and metastatic non-small cell lung carcinoma. It was approved by FDA in 2015 for the treatment… Expand
VEGF inhibition in urothelial cancer: the past, present and future
TLDR
Anti-angiogenic agents have shown promise in recent studies treating locally advanced or metastatic urothelial cancer, however, further work is needed to elucidate ideal treatment combinations in selected patient populations to maximize benefit. Expand
New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness
TLDR
How the antibody-based therapies will evolve, including the use of antibodies in combinations, their main characteristics, advantages, and how they could contribute to significantly increase the chances of success in cancer therapy are described. Expand
Clinical development of targeted and immune based anti-cancer therapies
Cancer is currently the second leading cause of death globally and is expected to be responsible for approximately 9.6 million deaths in 2018. With an unprecedented understanding of the molecularExpand
Gastric cancer management: Kinases as a target therapy
TLDR
The mutational landscape of gastric cancer, the use of kinase inhibitors as targeted therapies in gastric tumours and the clinical trials underway for novel inhibitors are examined, highlighting successes, failures and future directions. Expand
Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art
TLDR
HAI chemotherapy was applied for the treatment of advanced hepatobiliary cancers with encouraging results, however, the efficacy of this treatment strategy remains controversial. Expand
Paradoxical capillary hemangioma during treatment with ramucirumab
TLDR
The patient developed an asymptomatic slightly indurated 10 cm purplish-red plaque with serpiginous borders over the scar caused by the drainage of his gastroesophageal surgery in the right hemiabdomen and the histological diagnosis was capillary hemangioma secondary to ramucirumab therapy. Expand
Systemic therapy for hepatocellular carcinoma: beyond sorafenib.
TLDR
Systemic treatments for incurable HCC beyond sorafenib will be explored, with particular emphasis to various kinase inhibitors, immunotherapies, and new data on combination therapies. Expand
Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
TLDR
The challenge is now placed on how to best select, combine, and sequence drugs with the goal of improving efficacy and minimizing toxicities to deliver better outcomes for HCC patients. Expand
Introduction to Cancer Stem Cells: Past, Present, and Future.
TLDR
The discovery and characterization of cancer stem cells populations within several major cancer subtypes, recent developments of novel assays used in studying therapy resistant tumor cells, as well as recent developments in therapies targeted at cancer stem Cells are reviewed. Expand
Nucleic Acid-Based Approaches for Tumor Therapy
TLDR
This review intends to provide a comprehensive overview of the current state of the therapeutic use of nucleic acids for cancer treatment on various levels, comprising mRNA and DNA-based vaccines to be expressed by antigen presenting cells evoking sustained anti-tumor T cell responses. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 41 REFERENCES
Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC.
TLDR
Despite the positive results seen in REVEL, the exact role of ramucirumab in the treatment paradigm of lung cancer remains to be seen given the modest survival benefit of 1.4 months and the lack of predictive biomarkers at this time. Expand
Targeted inhibition of VEGF receptor 2: an update on ramucirumab
TLDR
The purpose of this article is to review the preclinical motivation for VEGFR2-targeted therapies and survey recent data from clinical trials involving ramucirumab, as well as highlight ongoing studies. Expand
A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
TLDR
Ramucirumab monotherapy may confer anticancer activity in advanced hepatocellular carcinoma with an acceptable safety profile and exploratory biomarker studies showed changes in circulating VEGF, PlGF, and sVEGFR-2 that are consistent with those seen with other anti-VEGF agents. Expand
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.
TLDR
Ramucirumab may enhance the efficacy of modified FOLFOX-6 chemotherapy with an acceptable safety profile in metastatic CRC. Expand
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
TLDR
Although antitumor activity was observed, the predetermined efficacy endpoints were not met, and Pharmacodynamic analyses revealed changes in several circulating V EGF proteins following initial ramucirumab infusion, including increased VEGF-A, PlGF and decreased sVEGFR-2. Expand
Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC).
TLDR
This multicenter US study found that the addition of RAM to E would increase progression-free survival (PFS) in comparison to E alone as third- to fifth-line therapy in patients with MBC. Expand
A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy
TLDR
The clinical efficacy and safety of ramucirumab in patients with TKI‐resistant/intolerant mRCC are investigated. Expand
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
  • J. Spratlin, R. Cohen, +14 authors S. Eckhardt
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
Objective antitumor activity and antiangiogenic effects were observed over a wide range of dose levels, suggesting that ramucirumab may have a favorable therapeutic index in treating malignancies amenable to VEGFR-2 inhibition. Expand
Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.
TLDR
Addition of ramucirumab to docetaxel in HER2-negative advanced breast cancer did not meaningfully improve important clinical outcomes. Expand
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
TLDR
Ramucirumab is the first biological treatment given as a single drug that has survival benefits in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after first-line chemotherapy, and validate VEGFR-2 signalling as an important therapeutic target in advanced Gastric cancer. Expand
...
1
2
3
4
5
...